Oral Therapies in Psoriasis Management: A Debate on Deucravacitinib vs Apremilast - Episode 3
Comparing the Head-to-Head Efficacy of Deucravacitinib and Apremilast in Pivotal Clinical Trials
Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.
Panelists discuss how clinical trial data demonstrate the superior efficacy of deucravacitinib over apremilast in moderate to severe psoriasis. Referencing the POETYK studies, they highlight markedly higher PASI 75 and PASI 90 response rates with deucravacitinib compared with apremilast. These findings reinforce the TYK2 inhibitor’s potency in achieving rapid and meaningful skin clearance.
Panelists discuss how apremilast remains a valuable option for patients prioritizing safety and tolerability, despite lower response rates. They emphasize that comparative trials reveal not only differences in efficacy but also nuances in patient experience, with deucravacitinib often providing faster onset of improvement and better outcomes for high-impact disease.
Panelists discuss how translating trial data into practice requires contextual judgment. Clinicians should balance efficacy with comorbidity risk, adherence potential, and patient goals, ensuring that oral therapy decisions align with individual treatment expectations.
